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ABSTRACT - Intercellular communication is essential to maintain vital physiological activities and to 
regulate the organism’s phenotype. There are a number of ways in which cells communicate with one 
another. This can occur via autocrine signaling, endocrine signaling or by the transfer of molecular 
mediators across gap junctions. More recently communication via microvesicular shedding has gained 
important recognition as a significant pathway by which cells can coordinate the spread and dominance of 
selective traits within a population. Through this communication apparatus, cells can now acquire and secure 
a survival advantage, particularly in the context of malignant disease. This review aims to highlight some of 
the functions and implications of microparticles in physiology of various disease states, and present a novel 
therapeutic strategy through the regulation of microparticle production. 
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Microvesicles are shed from most eukaryotic 
cells, and serve as vectors of long and short range 
signaling, facilitating the exchange of cargo 
between donor and recipient cells (1-4). Various 
microvesicles have been defined, including 
microparticles (MPs), exosomes and apoptotic 
bodies, with each vesicle type expressing distinct 






MPs are small enclosed plasma membrane 
fragments, measuring 0.1-1 µm in diameter, that 
typically express phosphatidylserine (PS) on their 
surface (2). 
MPs are released from pre-apoptotic and 
activated cells by outward blebbing and 
vesiculation of the plasma membrane following a 
breakdown of the cytoskeleton, and play a central 
role in extracellular communication, 
inflammation, thrombosis, vascular function and 
oncogenic transformation (4, 7-13). 
MPs are emerging as messengers for cells, 
whereby they can alter vascular function and 
induce various biological responses (14-16). In 
their role as messengers, MPs carry molecular 
components of the parent cell such as membrane 
proteins, cytokines, integrins, transcription 
factors, nucleic acids and cytoplasmic contents, 
and can alter the activity of recipient cells through 
the transfer of their cargo (3, 4, 17, 18). This 
capacity has been implicated in long range cell 
signaling, coagulation, apoptosis, immune 




Apoptosis leads to the formation of apoptotic 
bodies, which are membrane-enclosed cell 
fragments similar in size to platelets (1-5 µm in 
diameter) (25). These fragments consist of 
cytoplasm, organelles and nuclear fragments and 
are implicated in cancer progression and 
immunosuppression (26-29). Apoptotic bodies 
externalise PS to promote phagocytosis and 




Exosomes are a smaller and more homogenous 
population of microvesicles, measuring 0.04-0.1 
µm in diameter (approximately same size as 
viruses) that are released by the exocytosis of 
multivesicular 
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bodies, and are formed by inward budding into 
the lumen at the endosomal limiting membrane 
(2, 33, 34). These multivesicular bodies fuse with 
the plasma membrane to release the small vesicles 
inside (the exosomes). Exosomes are released by 
most cell types, and contain cytosolic 
components, such as tetraspanin proteins, 
ribonucleic acids (RNAs), as well as cell surface 
proteins (2, 13, 35-38). 
After being released from their respective 
cells, exosomes will either remain in the 
proximity of the cell of origin or relocate to 
biological fluids such as plasma, urine, milk, 
bronchoalveolar fluid and tumour effusions, and 
thereby facilitate long-range biological signaling 
(39-43). 
 
Formation of Membrane-derived 
Microparticles 
 
As platelet MPs have been the most widely 
studied vesicles thus far, the majority of 
information regarding MP shedding is in the 
context of activated platelets. The mechanisms 
involved however are believed to be similar for 
most cell types (44, 45). 
Cell activation leading to MP formation is 
attributed to various stimuli such as serine 
proteases, thrombin, ADP, inflammatory 
cytokines (e.g. TNF), growth factors, shear and 
stress inducers (46-51). In contrast to this, 
apoptosis-induced MP release is regulated by the 
caspase-mediated Rho effector protein ‘Rho-
associated, coiled-coil containing protein kinase 
1’ (ROCK 1), and can also be stimulated by TNF 
and thrombin (50). 
 
Disruption of Phospholipid Asymmetry 
 
MPs are formed following disruption of the cell’s 
phospholipid asymmetry (52-54). Under steady 
state conditions, phosphatidylcholine (PC) and 
sphingomyelin (SM) are located predominately on 
the outer membrane leaflet, and PS and 
phosphatidylethanolamine (PE) are located on the 
inner membrane leaflet (55, 56). This asymmetric 
distribution is under the control of the membrane-
bound ATP-dependent enzymes; flippase and 
floppase, as well as the ATP-independent 
transporter scramblase (Figure 1) (57, 58). 
Flippase (the aminophospholipid translocase) 
rapidly directs phospholipids, specifically PS and 
PE, to the inner leaflet, whereas floppase 
promotes the much slower outward translocation 
of lipids (9). Scramblase is a bidirectional 
transporter and promotes random distribution of 
phospholipids across the plasma membrane 
bilayer (56, 59). 
Membrane reorganisation can occur under 
normal physiological conditions or in response to 
stimuli, such as following exposure to 
proinflammatory or prothrombotic substances, 
and involves the calcium-dependent inhibition of 
flippase and the promotion of scramblase and 
floppase activity (46, 56, 60). During this process, 
phospholipids, such as PS, are redistributed from 
the inner leaflet of the plasma membrane to the 
outer leaflet (9, 56, 61). 
 
Membrane Vesiculation and the Role of 
Calpain 
 
Following loss of phospholipid asymmetry, the 
anchorage between the membrane and 
cytoskeleton is disrupted. This allows for 
membrane vesiculation and subsequent MP 
release (45, 62). 
In the case of apoptosis-induced MP release, 
the process is regulated via the activation of 
ROCK 1. During apoptosis, activated caspases 
(cysteine proteases associated with apoptosis) 
cleave ROCK 1, which promotes the generation 
of contractile force that leads to the formation of 
membrane blebs, disruption of the cellular 
membrane structure and subsequent vesiculation 
(9, 48, 63). 
Conversely, the release of MPs from activated 
cells is associated with the activity of calpains. 
Calpains are intracellular cysteine proteinases, 
found in almost all eukaryotes and some 
prokaryotes, and play a central role in cellular 
functions such as cell cycle progression, gene 
expression, cytoskeleton cleavage, signal 
transduction, cell proliferation and MP formation 
(64-66). Calpain resides in the cytosol in its 
inactive form until an increase in cytosolic 
calcium translocates it to the cellular membrane 
where it is then activated (64). 
After phospholipid scrambling, calpain 
cleaves cytoskeletal talin and α-actin filaments 
that adhere the plasma membrane to the 
cytoskeleton, thereby allowing the release of MPs 
(Figure 2) (53, 67, 68). 
The calpain family consists of both tissue-
specific and ubiquitously expressed isoforms. The 
best characterised isoforms are the ubiquitously 
expressed µ-calpain and m-calpain, which are 
named according to the concentrations of Ca2+ 
required to activate them in vitro; micromolar for 
μ-calpain and millimolar for m-calpain (69, 70).  
 
 









































Figure 1. A) Schematic of a cellular membrane at rest. Phospholipid asymmetry is under the control of active flippase, 
whilst floppase and scramblase remain inactive. B) Cellular activation. Calcium is released from the endoplasmic 
reticulum, which can lead to the loss of phospholipid asymmetry and the activation of calpain. 
 







Figure 2. Cytoskeleton disruption. Activated Calpain cleaves the cytoskeleton, leading to the formation of a membrane 
bleb and subsequent MP release. 
 
 
These proteins function as hetero dimers and are 
composed of large 80 kDa catalytic subunits and a 
small common 28 kDa regulatory subunit. μ-
calpain is encoded by the gene CAPN 1, and m-
calpain is encoded by CAPN 2, with the common 
regulatory subunit being encoded by CAPN 4. 
This small subunit is identical for both enzymes 
and the large subunits share 55-65% sequence 
homology (64, 69, 71). 
Both µ-calpain and m-calpain can be 
subdivided into four domains. Domain II is the 
catalytic domain, conserved in all calpain 
isoforms, and is a triad site, which contains 
cysteine, histidine and asparagine residues. In 
human µ-calpain cysteine is located at residue 
115, while in m-calpain it is located at residue 105 
(69). 
Calpain activity is tightly regulated by 
calpastatin, the endogenous inhibitor of µ-calpain 
and m-calpain and other dimeric calpains (65, 72). 
Calpastatin is a ubiquitously expressed inhibitor 
with four inhibitory domains, that displays 
specificity for calpain over other cysteine 
proteases, and can reversibly inhibit up to four 
molecules of calpain at once by blocking the 
active sites of calpain (65, 69, 72). 
 
The Role of Microparticles in Homeostasis 
 
MPs play an important role in biological 
processes such as coagulation, intercellular 
communication, apoptosis and homeostasis (48, 
73, 74). 
Platelet and endothelial MPs circulating in 
blood express PS and tissue factor (TF) (the 
primary initiator of the extrinsic coagulation 
pathway) on their outer membrane. This exposed 
PS and TF provides a procoagulant surface for 
clotting enzymes in the coagulation cascade and 
therefore enables optimal thrombin generation 
(18, 75). 
A crucial role for MPs in clot formation has 
been demonstrated in vivo, using a mouse model 
of haemophilia (76). In this setting, as well as in 
human blood, procoagulant MP were generated 
by the interaction of P-selectin and its natural 
ligand, PSGL-1. 





MPs have been reported to express 
anticoagulant properties to balance their 
procoagulant activity. MPs indirectly down-
regulate thrombin generation by promoting the 
generation of plasmin, and thus maintain vascular 
integrity (77-79). 
MP-mediated cell signaling has also been 
implicated in the maintenance of homeostasis, 
with miRNAs that are predicted to regulate 
homeostasis and metabolic function being found 
in MPs circulating in the plasma of healthy 
donors (80). 
 




Reduced MP levels have been implicated in the 
physiological dysfunction seen in Scott syndrome, 
a very rare autosomal disorder, and the only 
human disease known to be caused by a lack of 
MP formation. This disorder is characterised by 
platelets, red blood cells and B-lymphoblasts 
lacking the ability to externalize PS and release 
MPs due to the abnormal expression of 
scramblase (2, 47, 57). The absence of PS 
exposure in this disorder results in severe 





In a seminal study by Mack et al. it was shown 
that MPs disseminate specific chemokine 
receptors required for the propagation of HIV-1 to 
receptor-negative cells (20). In order to infect 
target cells HIV-1 requires the expression of CD4, 
an immune cell glycoprotein, and virus co-
receptors which enable target cell binding and 
internalisation of viral particles (81). It was 
shown that various cell types release MPs 
containing the chemokine CCR5. These MPs are 
then able to transfer the receptor to CCR5- cells 
and render them susceptible to HIV-1 infection. 
This transfer and acquisition demonstrated the 
important role that MPs play in the dissemination 




Vascular disorder is closely linked to type 2 
diabetes, with 50% of diabetic deaths being 
attributed to cardiovascular disease (82). 
MP formation associated with type 2 diabetes 
has been implicated in the enhancement of 
thrombin generation and procoagulant activity, 
with endothelial-derived MPs and monocyte-
derived MPs reported to participate in the 
development of atherosclerosis in hyperlipidemic 
diabetic patients (83). With such a high death rate 
associated with symptoms secondary to the main 
disease, the modulation of MP release in the 
progression of diabetes could potentially help to 





Malaria is a life threatening disease caused by 
Plasmodium parasites that is estimated to cause 
up to 1 million deaths per year (84). 
Blood-borne Plasmodium falciparum is the 
most deadly species, and infection induces 
profound changes in the microvasculature, 
including TNF production, which leads to platelet 
adhesion, formation of endothelial-derived MPs, 
cerebral vascular inflammation and 
microcirculatory dysfunction (85-87). 
Patients with severe malaria exhibit increased 
plasma levels of endothelial MPs. Remarkably, 
these high levels were seen in the presence of 
neurological complications – a syndrome called 
cerebral malaria (CM) – but not in patients 
presenting only severe malarial anaemia. 
In CM, the major deleterious effects are not 
only attributed to the degree of infection itself, but 
to immune cell over-activation, resulting notably 
in cytokine storm, platelet activation and 
enhanced MP formation from various cellular 
origins (85, 87, 88). 
In the experimental model for CM, ABCA1-/- 
mice, which lack the floppase transporter required 
to externalise PS on MPs, were found to exhibit 
minimal vesiculation and complete resistance to 
CM, which suggests that MPs are directly 
implicated in the progression of the neurovascular 
pathology (14, 89, 90). 
In CM, increased release of MPs correlated 
with the acute phase of the condition and is a 
potentially useful diagnostic tool and patient 
management aid, as MP levels associated with 
acute neurological phase returned to normal levels 
during recovery (88, 91). 
Studies have concluded that the cellular 
origin, amount and composition of MPs can 
reflect the pathophysiological state and therefore 













Cancer-derived MPs were first reported in 1978 
when they were detected in cultures from a 
patient with Hodgkin disease (92). Tumour cells 
can produce MP constitutively without any 
apparent need for stimulus but vesiculation can be 
increased by stress including exposure to 
chemotherapeutic drugs and heat (6). 
Cancer patients not only exhibit tumour-
derived MP but also high levels of platelet-
derived MP (93). The hypercoagulation typically 
observed with malignancy can be attributed in 
part to these procoagulant MPs (94, 95). 
MPs have been shown to contribute to tumour 
survival and it has been postulated that tumour 
cells can evade apoptosis by releasing MPs that 
contain caspase-3, thereby preventing its 
intracellular accumulation (96). Inhibition of this 
release has been shown to result in caspase-3 
accumulation and subsequent apoptosis (96). 
To facilitate invasion, metastatic cancer cells 
can degrade the extracellular matrix (ECM) 
through the transfer of surface proteases such as 
matrix metalloproteinases (MMPs), urokinase-
type plasminogen activator (uPA) and cathepsins 
(97). Tumour cells have been shown to release 
MP rich in MMPs and uPA, which degrade the 
ECM, allowing for cell invasion (98). 
Tumour-derived MPs also carry regulatory 
miRNAs, mRNAs and bioactive lipids, and can 
transmit them to other cells within the body (4, 6, 
99, 100). Of particular concern is the MP assisted 
dissemination of cancer multidrug resistance, by 
which drug sensitive cells can acquire the 
resistance phenotype via long-range 




Multidrug resistance (MDR) is the phenomenon 
by which cancers become cross-resistant to a wide 
variety of functionally and structurally unrelated 
chemotherapeutic drugs and constitutes the most 
significant obstacle in successful cancer treatment 
(100, 101). 
MDR is predominately associated with the 
over-expression of the multidrug efflux 
transporters P-glycoprotein (P-gp/ABCB1) and 
Multidrug Resistance-Associated Protein 1 
(MRP1/ABCC1), which are both expressed in the 
cell membrane of resistant cancer cells (102). 
These transporters belong to the superfamily of 
ATP-binding cassette (ABC) proteins which have 
also been implicated in infectious diseases such as 
AIDS and malaria (86, 89, 103, 104). P-gp and 
MRP1 enable the maintenance of sublethal 
intracellular concentrations of chemotherapeutic 
drugs by facilitating the ATP-dependent efflux of 
anticancer agents, allowing the tumour to evade 
the toxic insult (100, 101, 104-107). 
The mechanism that allows these transporters 
to bind and efflux a broad repertoire of drugs 
remains as yet undefined. Since the discovery in 
1981 that verapamil and trifluoperazine could 
positively affect MDR by the modulation of P-gp, 
hundreds of drugs with different structures and 
activities, such as immunosuppressants, calcium 
channel blockers and steroids have been 
developed (108-110). Inhibitors of P-gp have 
been investigated in the prevention or 
circumvention of MDR clinically, with many 
showing positive effects in vitro, but proving to 
be unsuitable clinically due to dose limiting 
toxicity and lack of efficacy (111, 112). 
 
Microparticle Mediated MDR 
 
The over-expression of P-gp is known to be 
controlled by genetic and epigenetic mechanisms, 
and MDR acquisition through this process has 
been well characterised (113, 114). The spread of 
P-gp mediated MDR through non-genetic 
pathways however has been more recently 
reported, with direct membrane protein transfer 
occurring through direct cell-to-cell contact, shed 
MPs and tunneling nanotubles (23, 115). 
‘Non-genetic’ acquisition of MDR was first 
demonstrated by Levchenko et al. through direct 
cell-to-cell contact (116). It was shown that P-gp 
could be transferred from P-gp positive cells to P-
gp negative cells via direct cell-to-cell contact 
both in in vitro and in vivo, allowing previously 
drug-sensitive tumour cells to survive exposure to 
toxic levels of chemotherapeutic drugs. The 
acquired phenotype was transient in vivo, and 
required constant exposure to anti-cancer drugs or 
P-gp positive cells (116). 
Our laboratory was the first to report that 
MDR can be spread in the absence of cell-to-cell 
contact with MPs being shown to facilitate the 
‘non-genetic’ transfer of MDR from drug-
resistant cells to drug-sensitive cells (23). We 
observed that MPs (i) were spontaneously shed 
from P-gp expressing leukemia cells (VLB100), (ii) 
carry P-gp from the donor cells, (iii) bind to and 
transfer P-gp to recipient cells  and (iv) confer the 
multidrug resistance phenotype to drug sensitive 
cells in vitro in as little as four hours following 
MP exposure (23). 
Further investigation revealed that MDR 
breast adenocarcinoma cells (MCF-7/DX) also 





spontaneously shed MP bearing functional P-gp 
and can confer the resistance phenotype to drug-
sensitive recipient cells, demonstrating that 
cancerous cells of both haematological and non-
haematological origin are able to transfer MDR 
via this pathway (100). 
Validation of this MP mediated pathway was 
demonstrated in vivo using the MCF-7 murine 
tumour xenograph model. A single subcutaneous 
injection of P-gp positive MPs administered 
adjacent to the tumour mass, effectively resulted 
in the transfer of P-gp to the tumour core as early 
as 24 hours later. This acquired phenotype 
remained stable for at least two weeks without 
MP re-administration or exposure to a selective 
pressure (3). 
In a recent study we also showed that MPs 
exhibit tissue selectivity, with respect to the 
transfer of P-gp to recipient cells.  MPs derived 
from P-gp over-expressing breast adenocarcinoma 
cells (MCF-7/DX cells) selectively transfered P-
gp to malignant MCF-7 breast cells only. 
Conversely, MPs derived from P-gp over-
expressing human leukaemia cells (VLB100 cells) 
transferred P-gp and MRP1 to both malignant and 
non-malignant cells (3). This study demonstrates 
for the first time a tissue selective component in 
the transfer of MP cargo. 
MP also mediate the transfer of regulatory 
nucleic acids from drug-resistant cells to drug-
sensitive cells, and re-template the transcriptional 
landscape of recipient cells to reflect the donor 
cell (Figure 3) (4, 100). Further to this, we have 
shown that MPs transfer the transcripts that 
encode floppase and scramblase to recipient cells 
in vitro, as well as enzymes that are essential for 
miRNAs biogenesis (Drosha, Dicer and 
Argonaute) (4). The presence of these transcripts 
suggests that MPs could be capable of inducing 
vesiculation in recipient cells, as well as being 





Figure 3. Mechanism for MP-conferred MDR in vitro. MPs, containing functional P-gp and nucleic acids, are released 











It has been well established that MPs actively 
contribute to the development and progression of 
numerous pathologies (2, 117). Modulation of 
their release therefore has the potential to provide 
a novel pharmacological strategy for disease state 
management. 
There are currently a variety of inhibitors that 
have been identified as providing therapeutic 
potential in this regard. These include inhibitors 
of calpain activation, calcium channel blockers 




Due to the critical role calpain plays in MP 
release, targeting of calpain is a promising 
strategy to inhibit MP production. The 
development of potent and selective calpain 
inhibitors has received significant attention, as 
calpain has been implicated in several patho-
physiological conditions including cerebral 
ischemia, Alzheimer’s disease, Parkinson’s 
disease, muscular dystrophy, thrombotic platelet 
aggregation, multiple sclerosis and diabetes, (68, 
70, 118, 119). Unfortunately, most of this work 
has not examined the effects on MP production. 
In the following section we provide a general 
outline of calpain inhibitors, and then focus on 
developments made in the context of inhibition of 
MP production. 
Calpain inhibitors generally target the thiol-
containing cysteine residue within the enzyme’s 
catalytic domain. These inhibitors are broadly 
classified as reversible or irreversible depending 
on how they interact with cysteine, with both 
classes containing an electrophilic center, also 
referred to as a ‘warhead’. 
Reversible warheads include α-ketoesters, α-
ketoamides and aldehydes, which all form a 
hemithioacetal or ketal with the cysteine thiol 
(120-122). 
Irreversible warheads such as epoxides, α-
haloketones, vinyl sulfone and diazomethyl 
ketone form irreversible covalent adducts (123-
125). Irreversible inhibitors have received less 
attention in drug discovery due to the potential for 
unexpected or undesirable effects during 
treatment, as irreversible inhibition of calpain-
activated cell-cycle progression, for example, 
could potentially have deleterious outcomes (118, 
126). 
In both classes, the warheads are commonly 
attached to a peptide backbone that is structurally 
similar to endogenous substrates, thus assisting in 
binding to calpain’s catalytic site and correctly 
positioning the warhead near the cysteine residue 
(127). A drawback to these peptidyl inhibitors is 
that rapid degradation by proteinases likely limits 
their in vivo efficacy. To circumvent this, several 
peptidomimetic inhibitors have been developed, 
however reactivity and metabolic instability of the 
warhead, as well as low calpain isoform 
selectivity remain issues for these inhibitor 
classes (128). Allosteric inhibitors of calpain have 
also been developed and show promise as 
selective inhibitors with improved 
pharmacokinetic properties (129, 130). These 
non-peptide inhibitors bind at the regulatory 
calcium-binding domain and prevent 
conformational changes required to activate 
calpain (69, 72). 
As over-active calpain can induce aberrant 
MP release, potential inhibitors of its activity 
have been investigated in order to develop a novel 
treatment method for related disease states. 
The calpain inhibitors MDL-28170 (a 
peptidyl aldehyde) and E-64-D (a peptidyl 
epoxide), (Figure 4) have been shown to 
significantly reduce MP release from platelets 
activated by agonists such as calcium ionophore 
A23187, thrombin and collagen (131). Likewise, 
calpeptin (200 µg/mL), a membrane-permeable 
inhibitor, has been shown to strongly inhibit the 
generation of MPs (~70%) from thrombin and 
collagen activated platelets in vitro, by inhibiting 
calpain activity as well as intracellular calcium 
elevation and attenuating thrombotic effects (67, 
132). Due to their inhibitory activities these 
compounds have shown some potential as 
treatment options for MP-related conditions, 
however these compounds lack specificity for 
calpain (131, 133). 
Thiosulfinates are another class of 
compounds that have been shown to inhibit 
calpain (134). These compounds occur naturally 
in different Allium species (such as onion and 
garlic), vegetables that have been shown to have 
beneficial health effects in conditions such as 
hypertension, inflammation, cardiac disease and 
cancer (135). Three members of the thiosulfinate 
family allicin, Pr2TS and Me2TS (Figure 4) were 
shown to inhibit calpain activation in platelets, 
leading to potent anti-aggregation activities with 
IC50’s between 9 – 15 µM (119). Inhibition of 
aggregation was attributed to reduced calpain-
mediated talin activation and reduction in platelet 
MP production: at 100 µM MP production was 
strongly inhibited. 
 







Figure 4. A selection of compounds reported to inhibit the formation of MPs 
 
 
Calcium Channel Blockers 
 
An increase in intracellular calcium plays a key 
role in MP generation, thus inhibition of cellular 
calcium influx is another strategy used to decrease 
MP production. Indeed, the calcium channel 
blockers nifedipine and benidipine, developed to 
treat hypertension, are effective in reducing MP 
release by thrombin-activated platelets in patients 
suffering from transient ischemic attacks (TIA). 
Elevated levels of circulating platelet MP are 
observed in patients with TIA and are associated 
with small vessel thrombosis (136, 137). 
Nifedipine (30-60 mg/day), a dihydropyridine 
calcium channel blocker (Figure 4), decreased 
cytosolic calcium concentrations and was shown 
to significantly reduce platelet MP levels (~50%) 





in patients exhibiting TIA symptoms (138). As a 
short-term treatment, the administration of this 
drug to patients with TIA was shown to reduce 
the concentration of MPs in the circulation, 
however the drug did not appear to be a viable 
long-term treatment option as many of the 
patients suffered a recurrence of TIA whilst 
taking the drug (136, 138). Benidipine (4 
mg/day), also a dihydropyridine calcium channel 
blocker (Figure 4), was administered over a six-
month study to patients with diabetes mellitus to 
improve vascular dysfunction associated with 
monocyte and endothelial cell hypercoagulability. 
The administration of this drug resulted in 
decreased patient MP levels, and was shown to 
lower the blood pressure in hypertensive patients. 
(139). Whilst the outcomes for these drugs were 
positive, the patient MP levels were still much 
higher than in the healthy controls involved in the 
study (138, 139). This would suggest that whilst 
the effects are beneficial, further development of 





Compared to healthy individuals, diabetic patients 
have increased levels of platelet-derived MPs 
(PDMPs) and monocyte-derived MPs (MDMPs), 
with both types of MPs promoting procoagulant 
activity (140). Ticlopidine (Figure 4), a 
thienopyridine antiplatelet drug used in the 
treatment of arteriosclerosis obliterans, has been 
identified for the treatment of hypercoagulability 
in patients with diabetes mellitus (83). The 
administration of 200mg/day to diabetic patients 
was shown to significantly reduce the number of 
systemic PDMPs (~30%) and MDMPs (~20%), 
demonstrating potential to prevent cardiovascular 
complications associated with elevated MP 
production (141). However, like calcium channel 
blockers outlined above, these drugs were not 
able to reduce the amount of MP to a level 




Pantethine (Figure 4), a disulfide intermediate in 
the production of Coenzyme A, inhibits platelet 
aggregation in vitro and has been shown to down-
regulate TNF-activated MP release associated 
with CM, by modulating an early step of the 
inflammation-coagulation cascade (86). Mouse 
brain endothelial cells, incubated with 1 mM of 
pantethine for 24 hours showed a 51% reduction 
in MP formation, whilst in vivo mice treated with 
pantethine had no signs of the associated 
neurological syndrome and exhibited MP levels 
similar to uninfected mice (86). Cystamine 
(Figure 4), another low molecular weight 
disulfide, also showed comparable inhibition of 
MP formation in vitro, but induced toxic shock 
with pathogenic consequences in vivo (86). In 
contrast, pantethine was well tolerated and 
showed potential as an effective therapeutic agent 
(86). 
The monomeric analogues of these molecules, 
pantetheine and cysteamine (Figure 4), were also 
investigated but proved to be ineffective, 
indicating that the disulfide bond is necessary for 
inhibition. As yet, the mechanism of pantethine 




During CM, TNF-activated endothelial MP 
formation can be reduced by treatment with the 
low molecular weight purine compound (2-NH2-
6-Cl-9-[(5-dihydroxyboryl)-pentyl] purine), also 
known a LMP-420 (Figure 4). LMP-420 is a 
novel TNF-α inhibitor that produces strong anti-
inflammatory effects and prevents cytokine-
induced overproduction of MP release in response 
to activation by TNF-α as well as lymphotoxin-α 
(LT). MP release was shown to be significantly 
reduced in TNF-α or LT-activated human brain-
derived endothelial cells (HBEC-5i) that were 
treated with 50nM of LMP-420 (142). 
As MPs presenting in CM are inextricably 
linked with the inflammation-coagulation 
cascade, the inhibition of their formation could 
lead to a new therapeutic approach for increasing 




Rho-associated protein kinases (ROCKs) regulate 
the actin cytoskeleton, and have been implicated 
in cancer cell migration, tumour progression and 
formation of tumour-derived microvesicles (143). 
In light of this, ROCK inhibitors, such as Y-
27632 (Figure 4), have been developed as 
potential cancer therapies (144). 
Y-27632, a low-molecular-weight inhibitor 
has been shown to reduce tumour-cell 
propagation in vivo and thus could potentially be 
used in cancer therapy (93, 145). 
The treatment of HeLa cervical tumour cells, 
U87 brain tumour cells and MDA-MB-231 breast 
cancer cells with Y-27632 (5 µM) was shown to 
significantly reduce the number of MPs produced 
through the ROCK-dependent signaling pathway 





as well as eliminating the appearance of 
microvesicles on the cell surface (143). 
To date no ROCK inhibitors are used in 
clinical treatments of cancer, however data 
suggests they have the potential to reduce primary 





Since their discovery, MPs have been shown to 
play a significant role in a wide variety of 
diseases and infectious conditions besides their 
important function in normal cellular processes. 
Due to these deleterious effects, and common 
occurrence in such conditions, the inhibition of 
their formation presents an attractive treatment 
strategy. Inhibitors developed thus far have shown 
some promise in this field. 
Down-regulation of MP production in 
patients with diabetes has been shown to improve 
vascular dysfunction and lower blood pressure, 
whilst in mouse models, pantethine has been 
shown to reverse the effects of CM-related 
neurological syndrome. 
As MP production is inextricably linked to 
cancer progression, inhibiting their formation has 
the potential to interfere with the ability of the 
cancerous cells to proliferate, as well as their 
ability to confer MDR to sensitive cells. 
In light of the potential therapeutic effects of 
MP inhibitors, this area of research requires 
further development, as there are currently no 
specific or potent MP inhibitors available for the 
treatment of disease. Due to the widespread 
occurrence of aberrant MP release in many 
conditions, the development of MP inhibitors thus 
holds promise in providing a novel treatment 
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